Detalles de la búsqueda
1.
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Invest New Drugs
; 36(2): 230-239, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28808818
2.
Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program.
Hepatol Commun
; 8(5)2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38619432
3.
Preliminary evidence for changes in frontoparietal network connectivity in the early abstinence period in alcohol use disorder: a longitudinal resting-state functional magnetic resonance imaging study.
Front Psychiatry
; 14: 1185770, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37575566
4.
Dietary linoleic acid lowering alone does not lower arachidonic acid or endocannabinoids among women with overweight and obesity: A randomized, controlled trial.
Lipids
; 58(6): 271-284, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100748
5.
Common Factors Underlying Diverse Responses in Alcohol Use Disorder.
Psychiatr Res Clin Pract
; 3(2): 76-87, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34746678
6.
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
J Clin Oncol
; 35(14): 1561-1569, 2017 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28350521
7.
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
Clin Cancer Res
; 19(7): 1852-7, 2013 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23403637
8.
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
Clin Cancer Res
; 17(15): 5123-31, 2011 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21673063
9.
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Eur J Cancer
; 47(7): 997-1005, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21247755
10.
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Eur J Cancer
; 46(2): 340-7, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19945858
Resultados
1 -
10
de 10
1
Próxima >
>>